ViiV Healthcare has received approval in Canada for Triumeq (dolutegravir 50 mg, abacavir 600 mg and lamivudine 300 mg), indicated for the treatment of Human Immunodeficiency Virus (HIV-1) infection in adults. Triumeq  is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering patients living with HIV the option of a once-daily single-pill regimen  that combines the integrase strand transfer inhibitor (INSTI) Tivicay (dolutegravir), with Kivexa (a fixed dose combination of the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine). 

"Until we have a cure for HIV, we need new or different HIV medicines for patients.  Everyone at ViiV is very proud that we can now offer Canadian physicians and patients living with HIV the first single-pill regimen containing dolutegravir," said Gregory Reinaud, General Manager Canada, ViiV Healthcare.  "Today's approval of Triumeq also demonstrates our continued commitment to developing and providing new treatment options."

For more details, go to: http://www.digitaljournal.com/pr/2256499